The impact of Empagliflozin on chronic kidney disease patient regardless of diabetes: A review

Abstract

Empagliflozin usually considered as an antidiabetic medication but it shows other beneficial effects like reducing the mortality rate of heart failure patients with reduced ejection fraction and nephroprotective effect. Recent studies revealed that the drug decline the incidence of renal events including death from renal causes, as well as the risk of end stage renal failure regardless of Type II Diabetes Mellitus. Clinical trial related empagliflozin on CKD patient confirmed that it has a consistent effect on the disease progression. This review aim to analysing the impact of Empagliflozin on Chronic Kidney Disease patient regardless of Diabetes.